Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases

Por Uhrig, M., Sedlmair, M., Schlemmer, H.P., Hassel, J.C., Ganten, M.
Publicado em 2013

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

Por Hassel, J C, Sucker, A, Edler, L, Kurzen, H, Moll, I, Stresemann, C, Spieth, K, Mauch, C, Rass, K, Dummer, R, Schadendorf, D
Publicado em 2010

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

Por Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., Savage, K. J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H. B., Waxman, I. M., Abernethy, A. P.
Publicado no Ann Oncol (2016)

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

Por Schadendorf, D., Amonkar, M. M., Milhem, M., Grotzinger, K., Demidov, L. V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J. C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F. S., Patel, K., Casey, M., Robert, C.
Publicado no Ann Oncol (2014)

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Por Eggermont, A.M.M., Chiario-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J.D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P.A., Richards, J.M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J.S., Maio, M., Bastholt, L., Mortier, L., Thomas, L., Tahir, S., Hauschild, A., Hassel, J.C., Hodi, F.S., Taitt, C., de Pril, V., de Schaetzen, G., Suciu, S., Testori, A.
Publicado no N Engl J Med (2016)